Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype

Cancer Research

Volumn 58, Issue 4, 1998, Pages 829-833

  Zehbe, Ingeborg ^a,b   Wilander, Erik ^b   Delius, Hajo ^a   Tommasino, Massimo ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

ADULT; AGED; ARTICLE; FEMALE; FEMALE GENITAL TRACT CANCER; FEMALE GENITAL TRACT INFECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

BASE SEQUENCE; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; HUMANS; MUTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PROTEIN-TYROSINE KINASES; UTERINE CERVICAL NEOPLASMS; VARIATION (GENETICS);

EID: 0032519813     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Zur Hausen, H. Viruses in human cancers. Science (Washington DC), 254: 1167-1173, 1991.
2. Dyson, N., Howley, P. M., Münger, K., and Harlow, E. The human papillomavirus-16 E7 oncoprotein is able to bind to retinoblastoma gene product. Science (Washington DC), 243: 934-937, 1989.
3. Werness, B. A., Levine, A., and Howley, P. A. Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science (Washington DC), 248: 76-78, 1990.
4. Von Knebel Doeberitz, M., Rittmüller, C., Aengeneyndt, F., Jansen-Dürr, P., and Spitkovsky, D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRb interactions. J. Virol., 68: 2811-2821, 1994.
5. Bosch, F. X., Manos, M. M., Muñoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., and Shah, K. V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst., 87: 796-802, 1995.
6. Muñoz, N., Bosch, F. X., de Sanjosé, S., Tafur, L., Izarzugaza, I., Gili, M., Viladiu, P., Navarro, C., Martos, C., Ascunce, N., Gonzalez, L. C., Kaldor, J. M., Guerrero, E., Lörincz, A., Santamaria, M., Alonso de Ruiz, P., Aristizibal, N., and Shah, K. V. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int. J. Cancer, 52: 743-749, 1992.
7. Schiffman, M. H., Bauer, H. M., Hoover, R. N., Glass, A. G., Cadell, D. M., Rush, B. B., Scott, D. R., Sherman, M. E., Kurman, R. J., Wacholder, S., Stanton, C. K., and Manos, M. M. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst., 85: 958-964, 1993.
8. Matsukura, M., and Sugase, M. Identification of genital human papillomavirus in biopsy specimen: segregation of specific virus types in specific clinicopathologic lesions. Int. J. Cancer, 61: 13-22, 1995.
9. Zehbe, I., Rylander, E., Edlund, K., Wadell, G., and Wilander, E. Detection of human papillomavirus in cervical intra-epithelial neoplasia, using in situ hybridization and alternative polymerase chain reaction techniques. Virchows Arch., 428: 151-157, 1996.
10. Zehbe, I., and Wilander, E. Human papillomavirus infection and invasive cervical neoplasia: a study of prevalence and morphology. J. Pathol., 181: 270-275, 1997.
11. Von Knebel Doeberitz, M., Oltersdorf, T., Schwarz, E., and Gissmann, L. Correlation of modified human papillomavirus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res., 48: 3780-3786, 1988.
12. Jones, C. J., Brinton, L. A., Hamman, R. F., Stolley, P. D., Lehman, H. F., Levine, R. S., and Mallin, K. Risk factors for in situ cervical cancer results from a case-control study. Cancer Res., 50: 3657-3662, 1990.
13. Schiffman, M. H., Haley, N. J., Felton, J. S., Andrews, A. W., Kaslow, R. A., Lancaster, W. D., Kurman, R. J., Brinton, L. A., Lannom, L. B., and Hoffmann, D. Biochemical epidemiology of cervical neoplasia: measuring cigarette smoke constituents in the cervix. Cancer Res., 47: 3886-3888, 1987.
14. Moreno, V., Muñoz, N., Bosch, F. X., de Sanjosé, S., Gonzalez, L. C., Tafur, L., Gili, M., Izarzugaza, I., Navarro, C., Vergara, A., Viladiu, P., Ascunce, N., and Shah, K. V. Risk factors for progression of cervical intraepithelial neoplasm grade III to invasive cervical cancer. Cancer Epidemiol. Biomark. Prev., 4: 459-467, 1995.
15. Strand, A., Wilander, E., Zehbe, I., and Rylander, E. High-risk HPV persists after treatment of genital papillomavirus infection but not after treatment of cervical intraepithelial neoplasia. Acta Obstet. Gynecol. Scand., 76: 140-144, 1997.
16. Ho, G. Y. F., Burk, R. D., Klein, S., Kadish, A. S., Chang C. J., Palan, P., Basu, J, Tachezy, R., Lewis, R., and Romney, S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst., 87: 1365-1371, 1995.
17. Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., DeRouen, T. A., Galloway, D. A., Vernon, D., and Kiviat, N. B. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med., 327: 1272-1278, 1992.
18. Gustafsson, L., and Adami, H-O. Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br. J. Cancer, 60: 132-141, 1989.
19. Östör, A. G. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol., 12: 186-192, 1993.
20. Mitchell, M. F., Hittelman, W. N., Hong, W. K., Lotan, R., and Schottenfeld, D. The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. Cancer Epidemiol. Biomark. Prev., 3: 619-626, 1994.
21. Syrjänen, K., Kataja, V., Yliskoski, M., Chang, F., Syrjänen, S., and Saarikoski, S. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet. Gynecol., 79: 675-682, 1992.
22. Xi, L. F., Demers, G. W., Koutsky, L. A., Kiviat, N. B., Kuypers, J., Watts, D. H., Holmes, K. K., and Galloway, D. A. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J. Infect. Dis., 172: 747-755, 1995.
23. Alvarez-Salas, L. M., Wilczynski, P., Burger, R. A., Monk, B. J., and DiPaolo, J. A. Polymorphism of the HPV-16 E6 gene of cervical carcinoma. Int. J. Oncol., 7: 261-266, 1995.
24. Fujinaga, Y., Okazawa, K., Nishikawa, A., Yamakawa, Y., Fukushima, M., Kato, I., and Fujinaga, K. Sequence variation of human papillomavirus type 16 E7 in preinvasive and invasive cervical neoplasias. Virus Genes, 9: 85-92, 1994.
25. Yamada, T., Wheeler, C. M., Halpern, A. L., Stewart, A-C. M., Hildesheim, A., and Jenison, S. A. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2 and L1 coding segments. J. Virol., 69: 7743-7753, 1995.
26. Yamada, T., Manos, M. M., Peto, J., Greer, C. E., Muñoz, N., Bosch, F. X., and Wheeler, C. M. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J. Virol., 71: 2453-2472, 1997.
27. Ellis. J. R. M., Etherington, I., Galloway, D., Luesley, D., and Young, L. S. Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16. Lancet, 349: 1069-1070, 1997.
28. Londesborough, P., Ho, L., Terry, G., Cuzick, J., Wheeler, C. M., and Singer, A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int. J. Cancer (Predict. Oncol.), 69: 364-368, 1996.
29. Xi, L. F., Koutsky, L. A., Galloway, D. A., Kuypers, J., Hughes, J. P., Wheeler, C. M., Holmes, K. K., and Kiviat, N. B. Genomic variation of human papillomavirus type 16 and risk for high-grade cervical intraepithelial neoplasia. J. Nail. Cancer Inst., 89: 796-802, 1997.
30. Conrad-Stöppler, M., Ching, K., Sloppler, H., Clancy, K., Schlegel, R., and Icenogle, J. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J. Virol., 70: 6987-6993, 1996.
31. Seedorf, K., Krämmer, G., Dürst, M., Suhai, S., and Röwekamp, W. G. Human papillomavirus type 16 DNA sequence. Virology, 145: 181-185, 1985.
32. De Roda Husman, A-M., Walboomers, J. M. M., van den Brule, A. J. C., Meijer, C. J. L. M., and Snijders, P.J. F. The use of the general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol., 76: 1057-1062, 1933.
33. Zehbe, I., Evander, M., Edlund, K., Rylander, E., Wadell, G., and Wilander, E. Non-isotopic detection and typing of human papillomavirus (HPV) by use of polymerase chain reaction and single-strand conformation polymorphism (PCR-SSCP). Diagn. Mol. Pathol., 5: 206-213, 1996.
34. Eschle, D., Durst, M., ter Meulen, J., Luande, J., Eberhardt, H. C., Pawlita, M., and Gissmann, L. Geographical dependence of sequence variation in the E7 gene of human papillomavirus type 16. J. Gen. Virol., 73: 1829-1832, 1992.
35. Crook, T., Tidy, J. A., and Vousden, K. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and transactivation. Cell, 67: 547-556, 1991.
36. Foster, S. A., Demers, G. W., Etscheid, B. G., and Galloway, D. A. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol., 68: 5698-5705, 1994.
37. Slebos, R. J., Kessis, T. D., Chen, A. W., Han, S. M., Hedrick, L., and Cho, K. R. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro. Virology, 208: 111-120, 1995.
38. Kast, W. M., Brandt, R. M. P., Sidney, J., Drijfhout, J-M., Kubo, R. T., Grey, H. M., Melief, C. J. M., and Sette, A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol., 152: 3904-3912, 1994.
39. Van Ginkel, F. W., Van Cott, J. L., Kiyono, H., and McGhee, J. R. Mucosal immunity to human papillomavirus in the female reproductive tract. Papillomavirus Rep., 8: 1-10, 1997.
40. Grassmann, K., Wilczynski, S. P., Cook, N., Rapp, B., and Iftner, T. HPV6 variants from malignant tumors with sequence alterations in the regulatory region do not reveal differences in the activities of the oncogene promoters but do contain amino acid exchanges in the Eo and E7 proteins. Virology, 223: 185-197, 1996.
41. Icenogle, J. P., Sathya, P., Miller, D. L., Tucker, R. A., and Rawls, W. E. Nucleotide and amino acid sequence variation in the L1 and E7 open reading frames of human papillomavirus type 6 and type 16. Virology, 184: 101-107, 1991.
42. Phelps, W. C., Münger, K., Yee C. L., Barnes, J. A., and Howley, P. M. Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J. Virol., 66: 2418-2427, 1992.
43. Strauss, H. J., Davies, H., Sadovnikova, E., Chain, B., Horowitz, N., and Sinclair, C. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc. Natl. Acad. Sci. USA, 89: 7871-7875, 1992.
44. Kadish, A. S., Romney, S. L., Ledwidge, R., Tindle, R., Fernando, G. J. P., Zee, S. Y., van Ranst, M. A., and Burk, R. D. Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix, whereas serological reactivity is not type-specific. J. Gen. Virol., 75: 2277-2284, 1994.